Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation

Area of Science:

• Pharmacology
• Drug Metabolism
• Toxicology

Background:

• Lapatinib, a tyrosine kinase inhibitor, can cause rare but severe liver injury.
• Cytochromes P450 (CYP3A4 and CYP3A5) are involved in lapatinib's bioactivation to a reactive quinone imine.
• The influence of CYP3A5 genetic variations on lapatinib metabolism remains unclear.

Purpose of the Study:

• To investigate the impact of CYP3A5 genotype and individual CYP3A activity on lapatinib metabolic activation.
• To correlate CYP3A and CYP3A5 activity with lapatinib metabolite formation in human liver systems.

Main Methods:

• Metabolism studies using CYP3A5-genotyped human liver microsomes and hepatocytes.
• Measurement of CYP3A and CYP3A5 activities using probe substrates (midazolam, T-5).
• Quantification of lapatinib metabolites via HPLC-tandem mass spectrometry and use of chemical inhibitors.

Main Results:

• Lapatinib O-debenzylation and quinone imine-GSH conjugate formation strongly correlated with hepatic CYP3A activity.
• CYP3A4 was the primary enzyme in lapatinib bioactivation across all tested liver tissues.
• CYP3A5 contributed 20%-42% to O-debenzylation in CYP3A5 expressers, with variable individual impact.

Conclusions:

• Individual hepatic CYP3A activity, rather than CYP3A5 genotype alone, is a key determinant of lapatinib bioactivation.
• Understanding individual CYP3A activity is essential for predicting exposure to potentially toxic lapatinib metabolites.
• This research provides critical insights into inter-individual variability in lapatinib metabolism and associated hepatotoxicity risk.